Acute leukaemia during tamoxifen therapy

Medical Oncology

Volumn 14, Issue 1, 1997, Pages 61-62

  Yalçin, Şuayib ^a   Güllü, Ibrahim ^a   Demiroǧlu, Haluk ^a   Tekuzman, Gülten ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Acute leukaemia; Secondary malignancy; Tamoxifen

Indexed keywords

TAMOXIFEN;

ACUTE LEUKEMIA; ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CASE REPORT; FEMALE; GENOTOXICITY; HUMAN; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; TAMOXIFEN;

EID: 0030844436     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Systemic treatment of early breast cancer by hormonal cytotoxic, or immune therapy. 133 Randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialisf Collaborative Group (1992) Lancet 339, 1-15.
2. Rutquist, L.E., Johansson, H., Signomklao, T. et al. (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J. Natl. Cancer Inst. 87, 654-51.
3. Fisher, B., Costantino, J.P., Redmond, C.K. et al. (1994) Endometrium cancer in Tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel project (NSABP) B-14. J. Natl Cancer Inst. 86, 527-37.
4. White, I.N., de Matteis, F., Davies, A. et al. (1992). Genomic potential of tamoxifen and analogs in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 13, 2197-2203.
5. Powles, T.J. and Hickish, T. (1995) Tamoxifen therapy and carcinogenic risk. J. Natl. Cancer Inst. 87, 1343-5.